Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Shenzhen Salubris Pharmaceuticals Co., Ltd. clinical trials
Part of 信立泰药业有限公司 (Hong Kong), which holds 56.99% as of 2025-12-31. Source
The registry lists 48 studies whose lead sponsor is Shenzhen Salubris Pharmaceuticals Co., Ltd. or one of 2 companies grouped under it. 18 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.
Keep track of what changes. Save the Shenzhen Salubris Pharmaceuticals Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Shenzhen Salubris Pharmaceuticals Co., Ltd..
- Shenzhen Salubris Pharmaceuticals Co., Ltd.41 studiesSame company
Something wrong?
- Salubris Biotherapeutics Inc6 studies →Subsidiary
Something wrong?
- ShenZhen KYD Biomedical Technology Co., Ltd.1 study →Acquired — became part of Shenzhen Salubris Pharmaceuticals Co., Ltd., Nov 30, 2015 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 48 of 48.
- An Extension Trial of GW 906 in Participants With Essential HypertensionRecruitingNCT07879755Not applicable
- A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive MedicationsNot yet recruitingNCT07835984Phase 2
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular EventsNot yet recruitingNCT07729475Phase 2
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy ParticipantsNot yet recruitingNCT07722299Phase 1
- A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled HypertensionRecruitingNCT07654140Phase 2
- A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney DiseaseNot yet recruitingNCT07647133Phase 2
- A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary AldosteronismNot yet recruitingNCT07646535Phase 2
- A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing RegimensRecruitingNCT07579936Phase 2
- Bioequivalence Study of Sacubitril Alisartan Amlodipine TabletsNot yet recruitingNCT07486453Phase 1
- Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic CancerRecruitingNCT06667960Phase 1/2
Sponsor listed in the registry: Salubris Biotherapeutics Inc
- Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy SubjectsEnrolling by invitationNCT07384104Phase 1
- Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese ParticipantsRecruitingNCT07174830Phase 4
- Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD PatientsNot yet recruitingNCT07079579Phase 4
- SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese PopulationRecruitingNCT07051603Phase 1
- Bioequivalence Study of Fluvastatin Sodium Extended Release Tablets in Healthy ParticipantsNot yet recruitingNCT06830954Phase 1
- SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid MalignanciesRecruitingNCT06737081Phase 2
- Evaluating the Safety and Efficacy of the G-stream® Drug-Eluting Stent in the Above-the-Knee Femoropopliteal ArteryRecruitingNCT05780359Not applicable
- Sirolimus DEB in Coronary Bifurcation LesionsRecruitingNCT04896177Not applicable
- The First-in-Human Study of GW906 InjectionCompletedNCT07884461Phase 1
- A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential HypertensionActive, not recruitingNCT07835971Phase 2
- A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionCompletedNCT07790120Phase 3
- SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a)Active, not recruitingNCT07745114Phase 1
- A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)Active, not recruitingNCT07716618Phase 2
- Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/AllisartanCompletedNCT07704697Phase 3
- Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With AmlodipineCompletedNCT07704684Phase 3
- Study of JK07 in Patients With Chronic Heart FailureActive, not recruitingNCT06369298Phase 2
Sponsor listed in the registry: Salubris Biotherapeutics Inc
- Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary HypertensionWithdrawnNCT07221513Phase 2
Sponsor listed in the registry: Salubris Biotherapeutics Inc
- A Study of SAL003 in Participants With Hypercholesterolemia and Mixed DyslipidemiaCompletedNCT07295418Phase 3
- A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed DyslipidemiaCompletedNCT07278830Phase 2
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed DyslipidemiaCompletedNCT07253584Phase 3
- Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)CompletedNCT04210375Phase 1
Sponsor listed in the registry: Salubris Biotherapeutics Inc
- To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture RiskCompletedNCT07028320Phase 3
- To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy SubjectsActive, not recruitingNCT07030504Phase 1
- The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal InsufficiencyCompletedNCT06883656Phase 1
- Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance HemodialysisCompletedNCT06720025Phase 3
- Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal DialysisCompletedNCT06720233Phase 3
- Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerActive, not recruitingNCT05620134Phase 1/2
Sponsor listed in the registry: Salubris Biotherapeutics Inc
- SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney DiseaseCompletedNCT06016036Phase 3
- To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan IsoproxilCompletedNCT06500689Phase 3
- To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan IsoproxilCompletedNCT06465264Phase 3
- SaExten Vena Cava Filter System in Prevention of Pulmonary EmbolismCompletedNCT04948502Not applicable
Sponsor listed in the registry: ShenZhen KYD Biomedical Technology Co., Ltd. · First submitted after ShenZhen KYD Biomedical Technology Co., Ltd. became part of Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Single-Ascending Dose Study of JK07 in Subjects With HFpEFWithdrawnNCT05322616Phase 1
Sponsor listed in the registry: Salubris Biotherapeutics Inc
- SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by MetforminCompletedNCT05801627Phase 3
- SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseCompletedNCT05782192Phase 3
- Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese AdultsCompletedNCT04747392Phase 1
- G56W1 in Women With Postmenopausal OsteoporosisStatus unknownNCT03720886Phase 1/2
- Recombinant SeV-hFGF2/dF Injection for PAODStatus unknownNCT03668353Phase 1
- Bivalirudin in Acute Myocardial InfarctionStatus unknownNCT02897037Phase 3